Humoral and cell-mediated immunity to human papillomavirus type I (HPV-i) in human warts
Article first published online: 29 JUL 2006
British Journal of Dermatology
Volume 108, Issue 6, pages 665–672, June 1983
How to Cite
KIENZLER, J.L., LEMOINE, M.TH., ORTH, G., JIBARD, N., BLANC, D., LAURENT, R. and AGACHE, P. (1983), Humoral and cell-mediated immunity to human papillomavirus type I (HPV-i) in human warts. British Journal of Dermatology, 108: 665–672. doi: 10.1111/j.1365-2133.1983.tb01078.x
- Issue published online: 29 JUL 2006
- Article first published online: 29 JUL 2006
- Accepted for publication 1 November 1982
The humoral and cell-mediated immune response to human papillomavirus type i (HPV-i) has been studied in 162 patients carrying papillomas of various clinical types: deep plantar wart or myrmecia, common wart, flat wart, and anogenital wart. Circulating antibodies were detected by immunodiffusion and microcomplement fixation, using purified HPV-i particles as type-specific antigen. A significant association between myrmecia and anti-HPV-i antibodies was found (39% of the cases).
Cell-mediated immunity was evaluated by a study of delayed hypersensitivity (DH). The main capsid components of HPV-i (HPV-i CP), consisting mostly of a polypeptide of molecular weight 54,000, were injected intradermally. In addition to the type-specific antigens, HPV-i CP contain other antigenic determinants shared by various types of human papillomaviruses and masked in intact viral particles. The DH tests to HPV-i CP showed no differences between the carriers of different papilloma types, confirming the presence of common antigenic determinants. Moreover, they gave rise to an increase or to new anti-HPV-i antibody production mostly in myrmecia carriers (78% and 33% of the cases, respectively), and to new DH to HPV-i CP in all groups of papilloma carriers (33% to 56%, depending on the clinical papilloma type).